AstraZeneca's Breast Cancer Drug Missed Targets in Phase Three Trial

By Christian Moess Laursen

AstraZeneca's breast cancer drug datopotamab deruxtecan didn't show a statistical significance in overall survival compared with chemotherapy, results showed at a phase three trial.

The Anglo-Swedish pharmaceutical giant said Monday that the treatment didn't achieve statistical significance in the final, overall survival analysis in patients with inoperable or metastatic hormone receptor-positive, HER2-low or negative breast cancer, previously treated with endocrine-based therapy and at least one systemic therapy.

Executive Vice President Susan Galbraith said the metastatic HR-positive breast cancer treatment landscape has advanced a lot in the last several years.

"Based on the TROPION-Breast01 results, there is evidence of the clinical value of datopotamab deruxtecan in this setting," Galbraith said.

"We will continue discussions with regulatory authorities and apply insights from these results to our clinical development program for datopotamab deruxtecan in breast cancer," she added.

AstraZeneca is jointly developing the datopotamab deruxtecan drug with Japanese peer Daiichi Sankyo.

The treatment had previously met the dual primary endpoint of progression-free survival.

Write to Christian Moess Laursen at christian.moess@wsj.com

(END) Dow Jones Newswires

September 23, 2024 02:40 ET (06:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.